First Trust NASDAQ Clean Edge Green Energy Idx Fd vs TransMedics Group Inc — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $49.35, while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| QCLN | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $68.47 | $150.42 |
52-Week Low | $37.69 | $61.99 |
Market Cap | — | $3.06B |
Enterprise Value | — | $3.46B |
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $50.57, up 2.31% today, with a bullish technical signal overall despite bearish moving averages. The ETF is positioned to benefit from global renewable energy acceleration driven by geopolitical tensions and rising data center power demand. Recent news highlights its sensitivity to U.S. political outcomes and federal clean energy policy, with historical outperformance ahead of midterm elections.
The outlook is supported by structural tailwinds in clean energy adoption, but risks include regulatory uncertainty and permit delays under current U.S. administration. Investment appeal hinges on policy continuity and execution of global renewable projects, with volatility expected around political developments.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Trailing returns across standard periods
Latest headlines on both assets
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →